Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s share price dropped 5.4% on Tuesday . The company traded as low as $9.40 and last traded at $9.40. Approximately 170,724 shares traded hands during trading, a decline of 65% from the average daily volume of 494,506 shares. The stock had previously closed at $9.94.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Oppenheimer boosted their price target on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a report on Friday, February 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a report on Friday, February 21st. Chardan Capital reaffirmed a "buy" rating and set a $40.00 target price on shares of Prothena in a research note on Friday, February 21st. StockNews.com raised Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Finally, Royal Bank of Canada cut their price objective on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a report on Friday, February 21st. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $55.00.
Get Our Latest Report on Prothena
Prothena Price Performance
The firm has a market capitalization of $495.21 million, a PE ratio of -4.00 and a beta of 0.07. The firm has a 50-day simple moving average of $12.89 and a 200-day simple moving average of $14.43.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). The business had revenue of $2.12 million during the quarter, compared to analysts' expectations of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. Equities analysts expect that Prothena Co. plc will post -4.04 earnings per share for the current year.
Institutional Investors Weigh In On Prothena
Several large investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC boosted its stake in Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after buying an additional 833 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Prothena by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,065 shares in the last quarter. Rhumbline Advisers raised its stake in Prothena by 1.8% during the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock valued at $930,000 after purchasing an additional 1,175 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Prothena by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 1,551 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Prothena by 4.0% in the 4th quarter. Invesco Ltd. now owns 42,846 shares of the biotechnology company's stock worth $593,000 after buying an additional 1,632 shares in the last quarter. 97.08% of the stock is owned by institutional investors.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
